This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Human Genome Sciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Human Genome Sciences Inc. (HGSI)

Q1 2012 Results Earnings Call

April 24, 2012 4:30 PM ET

Executives

Tom Watkins – President and CEO

Barry Labinger – Executive Vice President and Chief Commercial Officer

David Southwell – Executive Vice President and CFO

Dave Stump – Executive Vice President, Research and Development

Analysts

Joe Schwartz – Leerink Swann

Cory Kasimov – JPMorgan

Chris Raymond – Robert Baird

Matthew Harrison – UBS

Les – ISI Group

Terence Flynn – Goldman Sachs

Charmaine Chan – RBC Capital Market

Nicholas Bishop – Cowen and Company

Jim Birchenough – BMO Capital

Laura Ekas – Canaccord

Liisa Bayko – JMP Securities

Ying Huang – Barclays

Echo He – Maxim Group

Presentation

Operator

Please standby. Good day, everyone. And welcome to Human Genome Sciences’ First Quarter 2012 Financial Results Conference Call and Webcast. Please note, today’s call is being recorded.

At this time, I will turn things over to Mr. Tom Watkins, President and Chief Executive Officer of Human Genome Sciences. Please go ahead, sir.

Tom Watkins

Thank you, Operator, and good afternoon, everyone. Before we begin, I would like to point out that we will be making forward-looking statements, which are based on our current intent, belief and expectations. These statements are subject to certain risks and uncertainties, and I encourage everyone to consult our SEC filings for additional detail.

We reported our first quarter financial results earlier this afternoon and the press release that we issued, as well as several slides that we will be discussing in this call are both posted on our website and that’s www.hgsi.com.

Now we do not plan to take you through the financial results in today call. Although, we will take any questions that you may have on the first quarter later in this call.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs